Slominski Andrzej, Semak Igor, Zjawiony Jordan, Wortsman Jacobo, Li Wei, Szczesniewski Andre, Tuckey Robert C
Department of Pathology and Laboratory Medicine, University of Tennessee, Health Science Center, Memphis, TN 38163, USA.
FEBS J. 2005 Aug;272(16):4080-90. doi: 10.1111/j.1742-4658.2005.04819.x.
We show that cytochrome P450scc (CYP11A1) in either a reconstituted system or in isolated adrenal mitochondria can metabolize vitamin D3. The major products of the reaction with reconstituted enzyme were 20-hydroxycholecalciferol and 20,22-dihydroxycholecalciferol, with yields of 16 and 4%, respectively, of the original vitamin D3 substrate. Trihydroxycholecalciferol was a minor product, likely arising from further metabolism of dihydroxycholecalciferol. Based on NMR analysis and known properties of P450scc we propose that hydroxylation of vitamin D3 by P450scc occurs sequentially and stereospecifically with initial formation of 20(S)-hydroxyvitamin D3. P450scc did not metabolize 25-hydroxyvitamin D3, indicating that modification of C25 protected it against P450scc action. Adrenal mitochondria also metabolized vitamin D3 yielding 10 hydroxyderivatives, with UV spectra typical of vitamin D triene chromophores. Aminogluthimide inhibition showed that the three major metabolites, but not the others, resulted from P450scc action. It therefore appears that non-P450scc enzymes present in the adrenal cortex to some extent contribute to metabolism of vitamin D3. We conclude that purified P450scc in a reconstituted system or P450scc in adrenal mitochondria can add one hydroxyl group to vitamin D3 with subsequent hydroxylation being observed for reconstituted enzyme but not for adrenal mitochondria. Additional vitamin D3 metabolites arise from the action of other enzymes in adrenal mitochondria. These findings appear to define novel metabolic pathways involving vitamin D3 that remain to be characterized.
我们发现,在重组系统或分离的肾上腺线粒体中的细胞色素P450scc(CYP11A1)能够代谢维生素D3。与重组酶反应的主要产物是20-羟基胆钙化醇和20,22-二羟基胆钙化醇,分别占原始维生素D3底物的16%和4%。三羟基胆钙化醇是次要产物,可能是由二羟基胆钙化醇的进一步代谢产生的。基于核磁共振分析和P450scc的已知特性,我们提出P450scc对维生素D3的羟基化反应是顺序性和立体特异性的,最初形成20(S)-羟基维生素D3。P450scc不能代谢25-羟基维生素D3,这表明C25的修饰使其免受P450scc的作用。肾上腺线粒体也能代谢维生素D3,产生10种羟基衍生物,其紫外光谱具有维生素D三烯发色团的典型特征。氨鲁米特抑制实验表明,三种主要代谢产物是由P450scc作用产生的,而其他产物并非如此。因此,肾上腺皮质中存在的非P450scc酶在一定程度上参与了维生素D3的代谢。我们得出结论,重组系统中的纯化P450scc或肾上腺线粒体中的P450scc可以在维生素D3上添加一个羟基,随后观察到重组酶有进一步的羟基化反应,而肾上腺线粒体则没有。肾上腺线粒体中其他酶的作用产生了额外的维生素D3代谢产物。这些发现似乎定义了涉及维生素D3的新代谢途径,有待进一步表征。